Equities analysts expect BeyondSpring (NASDAQ:BYSI) to post ($0.76) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for BeyondSpring’s earnings, with the highest EPS estimate coming in at ($0.73) and the lowest estimate coming in at ($0.79). The business is expected to report its next quarterly earnings report on Friday, April 27th.
On average, analysts expect that BeyondSpring will report full-year earnings of ($4.41) per share for the current year. For the next fiscal year, analysts forecast that the firm will post earnings of ($3.71) per share, with EPS estimates ranging from ($4.53) to ($2.89). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow BeyondSpring.
BYSI has been the topic of several analyst reports. Maxim Group set a $52.00 price target on shares of BeyondSpring and gave the stock a “buy” rating in a research note on Thursday, December 14th. HC Wainwright set a $60.00 price target on shares of BeyondSpring and gave the stock a “buy” rating in a research note on Thursday, March 1st. Zacks Investment Research raised shares of BeyondSpring from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. Finally, Seaport Global Securities initiated coverage on shares of BeyondSpring in a research note on Tuesday, December 5th. They set a “buy” rating and a $56.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $54.50.
ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Anticipate BeyondSpring (BYSI) Will Post Earnings of -$0.76 Per Share” was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3299665/zacks-brokerages-anticipate-beyondspring-bysi-will-post-earnings-of-0-76-per-share.html.
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.